Abstract：
BACKGROUND: Schizophrenia (SCZ) is a severe mental disorder, but its pathogenesis is still unknown, and its clinical treatment effect is very limited. Transient receptor potential vanilloid 1 (TRPV1) channel and the Endocannabinoid System (ECS)have been confirmed to be involved in the pathogenesis of SCZ, although their actions have not been fully clarified yet. The objective is to examine TRPV1 and ECS expression in the blood of schizophrenia patients and investigate their correlation with disease severity.
METHODS: This is a cross-sectional investigation. Peripheral blood samples were gathered from normal controls (NC, n=37), as well as individuals with schizophrenia, including first episode (n=30) and recurrent (n=30) cases. We employed western blot and ELISA techniques to quantify TRPV1, cannabinoid receptors 1(CB1), anandamide (AEA), and 2-arachidonoylglycerol (2-AG), and assess the severity of the patient\'s symptoms by means of the PANSS scale.
RESULTS: Compared to NC, TRPV1 levels showed a noticeable decrease in both first episode schizophrenia (f-SCZ group) and recurrent schizophrenia (r-SCZ group) subjects. Additionally, CB1 levels appeared increased in f-SCZ group. Furthermore, 2-AG levels were found to be elevated in both f-SCZ group and r-SCZ group compared to NC, whereas AEA levels were decreased in f-SCZ group but increased in r-SCZ group. Moreover, among schizophrenia patients, TRPV1 demonstrated a negative correlation with negative symptoms. Within r-SCZ subjects, CB1 displayed a negative correlation with relapse number, while 2-AG showed a correlation in the opposite direction.
CONCLUSIONS: This study provides initial clinical evidence of changed TRPV1 expression in schizophrenia, potentially linked to negative symptoms. These results suggest a possible dysfunction of TRPV1 and the endocannabinoid system (ECS), which might offer new avenues for medical interventions.
METHODS: This is a cross-sectional investigation. Peripheral blood samples were gathered from normal controls (NC, n=37), as well as individuals with schizophrenia, including first episode (n=30) and recurrent (n=30) cases. We employed western blot and ELISA techniques to quantify TRPV1, cannabinoid receptors 1(CB1), anandamide (AEA), and 2-arachidonoylglycerol (2-AG), and assess the severity of the patient\'s symptoms by means of the PANSS scale.
RESULTS: Compared to NC, TRPV1 levels showed a noticeable decrease in both first episode schizophrenia (f-SCZ group) and recurrent schizophrenia (r-SCZ group) subjects. Additionally, CB1 levels appeared increased in f-SCZ group. Furthermore, 2-AG levels were found to be elevated in both f-SCZ group and r-SCZ group compared to NC, whereas AEA levels were decreased in f-SCZ group but increased in r-SCZ group. Moreover, among schizophrenia patients, TRPV1 demonstrated a negative correlation with negative symptoms. Within r-SCZ subjects, CB1 displayed a negative correlation with relapse number, while 2-AG showed a correlation in the opposite direction.
CONCLUSIONS: This study provides initial clinical evidence of changed TRPV1 expression in schizophrenia, potentially linked to negative symptoms. These results suggest a possible dysfunction of TRPV1 and the endocannabinoid system (ECS), which might offer new avenues for medical interventions.
摘要：
背景：精神分裂症（SCZ）是一种严重的精神障碍，但其发病机制尚不清楚,其临床治疗效果十分有限。瞬时受体电位香草素1（TRPV1）通道和内源性大麻素系统（ECS）已被证实参与SCZ的发病机制，尽管他们的行为尚未得到充分澄清。目的是检测TRPV1和ECS在精神分裂症患者血液中的表达，并探讨其与疾病严重程度的相关性。
方法：这是一项横断面调查。从正常对照组收集外周血样本(NC，n=37),以及精神分裂症患者，包括首发（n=30）和复发（n=30）例。我们采用蛋白质印迹和ELISA技术定量TRPV1，大麻素受体1（CB1），anandamide(AEA)，和2-花生四酰基甘油（2-AG），并通过PANSS量表评估患者症状的严重程度。
结果：与NC相比，TRPV1水平在首发精神分裂症（f-SCZ组）和复发性精神分裂症（r-SCZ组）受试者中均显示出显着下降。此外,f-SCZ组CB1水平升高。此外，与NC相比，f-SCZ组和r-SCZ组的2-AG水平均升高，f-SCZ组AEA水平降低，r-SCZ组AEA水平升高。此外，在精神分裂症患者中，TRPV1与阴性症状呈负相关。在r-SCZ受试者中，CB1与复发次数呈负相关,而2-AG显示出相反方向的相关性。
结论：这项研究提供了精神分裂症中TRPV1表达改变的初步临床证据，可能与阴性症状有关。这些结果表明，TRPV1和内源性大麻素系统（ECS）可能存在功能障碍，这可能为医疗干预提供新的途径。
方法：这是一项横断面调查。从正常对照组收集外周血样本(NC，n=37),以及精神分裂症患者，包括首发（n=30）和复发（n=30）例。我们采用蛋白质印迹和ELISA技术定量TRPV1，大麻素受体1（CB1），anandamide(AEA)，和2-花生四酰基甘油（2-AG），并通过PANSS量表评估患者症状的严重程度。
结果：与NC相比，TRPV1水平在首发精神分裂症（f-SCZ组）和复发性精神分裂症（r-SCZ组）受试者中均显示出显着下降。此外,f-SCZ组CB1水平升高。此外，与NC相比，f-SCZ组和r-SCZ组的2-AG水平均升高，f-SCZ组AEA水平降低，r-SCZ组AEA水平升高。此外，在精神分裂症患者中，TRPV1与阴性症状呈负相关。在r-SCZ受试者中，CB1与复发次数呈负相关,而2-AG显示出相反方向的相关性。
结论：这项研究提供了精神分裂症中TRPV1表达改变的初步临床证据，可能与阴性症状有关。这些结果表明，TRPV1和内源性大麻素系统（ECS）可能存在功能障碍，这可能为医疗干预提供新的途径。
